Skip to main content
Clinical Trials/NCT04113759
NCT04113759
Recruiting
Not Applicable

Postoperative Blood Flow Restriction Training Following Hip Arthroscopy: A Randomized Clinical Trial

Rush University Medical Center1 site in 1 country56 target enrollmentAugust 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Labral Tear, Glenoid
Sponsor
Rush University Medical Center
Enrollment
56
Locations
1
Primary Endpoint
Muscle size and appearance about the hip joint
Status
Recruiting
Last Updated
4 months ago

Overview

Brief Summary

This study will be a prospective randomized, double-blinded, placebo-controlled trial of patients undergoing primary hip arthroscopy for FAIS and/or labral pathology. All patients who sign the consent form will be enrolled in the study and randomized to one of the two treatment arms. Follow-up will take place at 1-month, 3-months, 6-months, and 1-year.

Detailed Description

The investigators propose using standardized strength testing, serial quadriceps measurements, and MRI to assess the efficacy of BFR training in increasing muscle hypertrophy following hip arthroscopy. Investigators will perform a randomized double-blinded placebo-controlled controlled trial of patients undergoing primary hip arthroscopy. Quadriceps strength will be measured with dynamometers at 3, 6, and 12 month time points, with Biodex strength testing at 6 and 12 months, postoperatively. Additionally, standardized circumferential leg measurements to assess quadriceps hypertrophy will be performed at 1, 3, 6 and 12-month time points. Patients will also undergo a hip MRI at 6 months postoperatively to quantify muscle size and appearance about the hip joint. Patient reported outcomes including standard outcomes measures at 3, 6, and 12 months and return to work/sport data will also be collected at standard time points. Patients will also be followed longitudinally for rates of reinjury, return to work, and return to sport. This study will evaluate the efficacy of BFR therapy in the postoperative period of primary hip arthroscopy to improve muscle hypertrophy during the short-term rehabilitation period. This will be directly measured by strength testing with dynamometers and Biodex testing. Other metrics will include standard validated patient reported outcomes at 3, 6 and 12 month time points including hip disability and osteoarthritis outcome score (HOOS), Harris Hip score (HHS), visual analog scale (VAS) for pain, international hip outcome tool (iHOT-12), and Hip outcome score (HOS), and return to sport questionnaires. Standardized serial circumferential thigh measurements will also be recorded at each visit, in additional to a one time MRI at 6 months postoperatively.

Registry
clinicaltrials.gov
Start Date
August 1, 2023
End Date
January 1, 2028
Last Updated
4 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult patients 18-40
  • English-speaking
  • Clinical and radiographic examination (MRI) consistent FAIS and/or labral pathology, and are schedule for primary hip arthroscopy
  • Written and informed consent for study participation

Exclusion Criteria

  • Patients younger than 18 or older than 40 years of age
  • Non-native English speaker
  • Revision surgery or prior history of ipsilateral hip or knee surgery
  • Inability to comply with the proposed follow-up clinic visits
  • Patients lacking decisional capacity
  • Patients with a history of deep vein thrombosis, pulmonary embolism, or known clotting disorder or hypercoagulable state
  • Pregnant or breast-feeding women. Pregnancy as determined by a positive pregnancy test prior to procedure. Females of childbearing potential must agree to use an acceptable birth control method during study participation.
  • Worker's compensation patients
  • Any clinically significant finding that would place the patient at health risk, impact the study, or affect the completion of the study
  • Any psychiatric illness that would prevent comprehension of the details and nature of the study and interfere with follow-up clinic visits

Outcomes

Primary Outcomes

Muscle size and appearance about the hip joint

Time Frame: 6 months postoperatively

To be assessed via hip MRI postoperatively

Biodex strength testing

Time Frame: 12 month time point

Isokinetic strength testing

Quadriceps Strength

Time Frame: 12 month time point

Will be measured with dynamometer

Standardized circumferential leg meaurements

Time Frame: 12 month time point

To assesss quadricep hypertrophy

Secondary Outcomes

  • Hip Outcome Score(12 month time point)
  • Visual Analog Scale for pain(12 month time point)
  • Hip Disability and Osteoarthritis Outcome Score(12 month time point)
  • Harris Hip Score(12 month time point)
  • International hip outcome tool(12 month time point)

Study Sites (1)

Loading locations...

Similar Trials